Insulet Corporation (PODD) shares soared 10.51% in pre-market trading on Friday, as investors reacted positively to a series of analyst upgrades for the medical device company specializing in insulin delivery systems.

The stock's significant uptick comes on the heels of multiple price target increases from prominent Wall Street firms. RBC Capital Markets raised its target price for Insulet to $330 from $325, while Wells Fargo adjusted its target to $330 from $322. Leerink Partners was the most bullish, increasing its price target to $333 from $314. These upgrades reflect growing confidence in Insulet's business prospects and potential for future growth.

Insulet, known for its Omnipod insulin management system, has been gaining traction in the diabetes care market. The collective analyst optimism suggests that the company may be well-positioned to capitalize on the increasing demand for innovative diabetes management solutions. Investors will likely be watching closely for Insulet's upcoming financial results and any new product developments to justify this renewed enthusiasm.